Clinical Trials Directory

Trials / Terminated

TerminatedNCT02067390

Urinary KIM-1 After Vancomycin or Linezolid Administration

Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury

Status
Terminated
Phase
Study type
Observational
Enrollment
5 (actual)
Sponsor
Midwestern University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute renal injury is a common complication of critical illness. Drug induced renal insult compounds the degree of injury in many patients, and a great deal of research has focused on prevention of this complication. Traditional biomarkers of renal injury like serum creatinine and blood urea nitrogen content fail to consistently predict harm among patients at risk. Kidney Injury Molecule 1 (KIM-1) will be studied as a biomarker of renal injury.

Detailed description

see above

Conditions

Timeline

Start date
2013-09-01
Primary completion
2019-05-01
Completion
2019-05-01
First posted
2014-02-20
Last updated
2020-02-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02067390. Inclusion in this directory is not an endorsement.

Urinary KIM-1 After Vancomycin or Linezolid Administration (NCT02067390) · Clinical Trials Directory